- Home
- GYRE vs HSTM Comparison
GYRE vs HSTM Comparison
Compare GYRE & HSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- HSTM
- Stock Information
- Founded
- GYRE 2002
- HSTM 1990
- Country
- GYRE United States
- HSTM United States
- Employees
- GYRE N/A
- HSTM N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- HSTM Computer Software: Programming Data Processing
- Sector
- GYRE Health Care
- HSTM Technology
- Exchange
- GYRE Nasdaq
- HSTM Nasdaq
- Market Cap
- GYRE 897.1M
- HSTM 864.6M
- IPO Year
- GYRE N/A
- HSTM 2000
- Fundamental
- Price
- GYRE $8.31
- HSTM $26.75
- Analyst Decision
- GYRE Strong Buy
- HSTM Hold
- Analyst Count
- GYRE 2
- HSTM 2
- Target Price
- GYRE $17.00
- HSTM $28.00
- AVG Volume (30 Days)
- GYRE 83.8K
- HSTM 165.9K
- Earning Date
- GYRE 11-12-2025
- HSTM 10-20-2025
- Dividend Yield
- GYRE N/A
- HSTM 0.47%
- EPS Growth
- GYRE N/A
- HSTM 14.03
- EPS
- GYRE 0.02
- HSTM 0.67
- Revenue
- GYRE $102,189,000.00
- HSTM $295,211,000.00
- Revenue This Year
- GYRE $16.80
- HSTM $4.91
- Revenue Next Year
- GYRE $50.29
- HSTM $5.11
- P/E Ratio
- GYRE $181.00
- HSTM $39.68
- Revenue Growth
- GYRE N/A
- HSTM 3.50
- 52 Week Low
- GYRE $6.11
- HSTM $25.00
- 52 Week High
- GYRE $19.00
- HSTM $34.24
- Technical
- Relative Strength Index (RSI)
- GYRE 56.93
- HSTM 45.20
- Support Level
- GYRE $8.17
- HSTM $25.00
- Resistance Level
- GYRE $9.42
- HSTM $27.27
- Average True Range (ATR)
- GYRE 0.39
- HSTM 0.65
- MACD
- GYRE 0.11
- HSTM -0.09
- Stochastic Oscillator
- GYRE 50.22
- HSTM 55.21
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
About HSTM HealthStream Inc.
HealthStream Inc provides workforce and provider solutions for healthcare organizations. Its reportable segments include Workforce Solutions and Provider Solutions. Workforce development solutions consist of SaaS, subscription-based products that are used by healthcare organizations. Its Provider Solutions products offer healthcare organizations software applications for administering and tracking provider credentialing, privileging, call center and enrollment activities. The company generates a majority of its revenue from Subscription Services.